Avita Medical Inc. reported its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2025. For Q4 2025, total revenue was USD 17.6 million, reflecting the lingering impact of reimbursement headwinds throughout the year. The company reported a gross profit margin of 81.2% for the quarter, influenced by product mix and inventory-related adjustments. Net use of cash improved sequentially for the second consecutive quarter to approximately USD 5.1 million, down from USD 6.2 million in the previous quarter, highlighting continued progress in cash efficiency. During the period, Avita Medical established a new credit facility with trailing twelve-month $(TTM)$ revenue covenants. The initial TTM revenue covenant is set at USD 68.5 million for the first quarter ending March 31, 2026, and USD 73 million for the full year 2026. Proceeds from the facility were used to repay outstanding debt, with the balance allocated to support growth in the company’s acute wound care portfolio. Avita Medical remains focused on disciplined cash management, sharpening execution, and accelerating commercial momentum in its core U.S. burn and trauma center business.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avita Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9654030-en) on February 12, 2026, and is solely responsible for the information contained therein.